Estimating Disability Adjusted Life Years using Survival Models in HIV/ AIDS Risk Groups
Introduction: Advances in human immunodeficiency virus (HIV) treatment have led to greater survival rates and have brought about a shift in the burden of disease from mortality to morbidity. The main purpose of this study is to estimate the Disability Adjusted Life Years (DALYs) of HIV infected patients associated with different modes of transmission.
Methods: Non-parametric Kaplan-Meier estimate has been utilised to develop survival function, and the mean residual life model has been utilised to estimate the life expectancy of patients alive at the end of the study. The impact of factors such as age, sex, hepatitis B and syphilis on life expectancy has also been assessed by fitting a proportional mean residual life model. DALYs have been calculated based on the results of both models.
Results: Retrospective time to event data of HIV patients undergoing Antiretroviral Therapy (ART) in Dr Ram Manohar Lohia Hospital, New Delhi, India has been utilised to illustrate the modelling technique. The study suggests that in total, 42300.15 DALYs were lost which includes 39765.10 years of life lost due to premature death and 2535.05 years of life lived with disability. When the covariates were taken into consideration, 47592.14 DALYs were found to have been lost with an average of 17.64 DALYs lost per patient.
Conclusion: Our results suggest that the high-risk groups such as homosexuals and parent to child transmission are a major cause of concern, which are in accordance with the existing national policies. Also, we would suggest that gender-based and age-based policies should be incorporated to reduce the burden of disease.
How to cite this article:
Grover G, Chakravarty S, Aggarwal S, Deo V. Estimating Disability Adjusted Life Years using Survival Models in HIV/ AIDS Risk Groups. J Commun Dis. 2021;53(4):36-47.
National AIDS Control Organization [Internet]. HIV facts & figures; [cited 2021 Jun 1]. Available from: http://naco.gov.in/hiv-facts-figures
National AIDS Control Organisation & ICMR-National Institute of Medical Statistics. India HIV Estimates 2020: Technical Brief. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India; 2021.
National AIDS Control Organization & ICMR-National Institute of Medical Statistics. India HIV Estimates 2019: Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India; 2020.
National AIDS Control Organization. Sankalak: Status of National AIDS Response. 2nd ed. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India; 2020.
National AIDS Control Organization. Operational guidelines for programme managers and service providers for strengthening STI/RTI services. NACO, Ministry of Health and Family Welfare, Government of India; 2011.
Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. J Int AIDS Soc. 2019;22:e25355. [PubMed] [Google Scholar]
Madi D, Achappa B, Vernakar P, Bhaskaran U, Ramapuram JT, Mahalingam S. Prevalence of Syphilis among People living with HIV (PLHIV) attending a tertiary care hospital in coastal south India. Asian J Med Sci. 2015;6(6):77-79. [Google Scholar]
Koli S, Girish Kumar CP, Selvaraj V, Prabu R, Chandrasekar C, Valan AS, Suria Kumar J, Raja K. Profile and prevalence of HBV among HIV affected individuals attending the largest public HIV care center in India. Virusdisease. 2016 Sep;27(3):215-9. [PubMed] [Google Scholar]
Murray CJL, Lopez AD. The Global Burden of Disease. Cambridge, MA: Harvard School of Public Health; 1996.
Schroeder SA. Incidence, prevalence, and hybrid approaches to calculating disability-adjusted life years. Popul Health Metr. 2012 Sep;10(1):1-7. [PubMed] [Google Scholar]
Tan-Torres Edejer T, Baltussen RM, Adam TA, Hutubessy R, Acharya A, Evans DB, Murray CJ. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organisation, Geneva (Switzerland); 2003. [Google Scholar]
Murray CJ, Lopez AD. Quantifying disability: data, methods and results. Bull World Health Organ. 1994;72(3):481-94. [PubMed] [Google Scholar]
Hilderink HB, Plasmans MH, Snijders BE, Boshuizen HC, Poos MJ, van Gool CH. Accounting for multimorbidity can affect the estimation of the Burden of Disease: a comparison of approaches. Arch Public Health. 2016 Aug;74:37. [PubMed] [Google Scholar]
Haagsma JA, van Beeck EF, Polinder S, Toet H, Panneman M, Bonsel GJ. The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches. Popul Health Metr. 2011 Apr;9:10. [PubMed] [Google Scholar]
Grover G, Aggarwal S. A study comparing cost-effectiveness of combination therapy for preventing opportunistic infections among human immunodeficiency virus–infected adults on antiretroviral therapy. Value Health Reg Issues. 2021 May;24:107-13. [PubMed] [Google Scholar]
Dandona L, Kumar SG, Kumar GA, Dandona R. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India. BMC Health Serv Res. 2010 May 10;10:117. [PubMed] [Google Scholar]
Chu PC, Wang JD, Hwang JS, Chang YY. Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high‐censored rates. Value Health. 2008 Dec;11(7):1102-9. [PubMed] [Google Scholar]
Struijk EA, May AM, Beulens JW, de Wit GA, Boer JM, Onland-Moret NC, van der Schouw YT, Bueno-de-Mesquita HB, Hoekstra J, Peeters PH. Development of methodology for disability-adjusted life years (DALYs) calculation based on real-life data. PLoS One. 2013 Sep;8(9):e74294. [PubMed] [Google Scholar]
Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: disability adjusted life year (DALY). In: Zaletel-Kragelj L, Boţikov J, editors. Methods and tools in Public Health. 2010:715. [Google Scholar]
Murray CJ, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions (No. 2). Harvard University Press; 1996. [Google Scholar]
Gupta RC, Bradley DM. Representing the mean residual life in terms of the failure rate. Math Comput Model Dyn Syst. 2003;37(12-13):1271-80. [Google Scholar]
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-81. [Google Scholar]
Jeong JH. Statistical inference on residual life. Springer; 2014. [Google Scholar]
Gumbel EI. Eine Darstellung der Sterbetafel. Biometrika; 1924:283-96. German. [Google Scholar]
Cox DR. Renewal Theory. London: Methuen; 1962.
Oakes D, Dasu T. A note on residual life. Biometrika. 1990;77(2):409-10. [Google Scholar]
Gower JC. A general coefficient of similarity and some of its properties. Biometrics; 1971. p. 857-71. [Google Scholar]
García-Laencina PJ, Abreu PH, Abreu MH, Afonoso N. Missing data imputation on the 5-year survival prediction of breast cancer patients with unknown discrete values. Comput Biol Med. 2015 Apr;59:125-33. [PubMed] [Google Scholar]
Batista GE, Monard MC. An analysis of four missing data treatment methods for supervised learning. Appl Artif Intell. 2003;17(5-6):519-33. [Google Scholar]
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012 Sep-Oct;15(6):835-42. [PubMed] [Google Scholar]
Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2010 (GBD 2010) Disability Weights. Seattle, United States of America; 2012.
Agrawal A, Goyal A, Goyal S, Kumari S, Singh PK. Seroprevalence of hepatitis B and syphilis co-infection in human immunodeficiency virus-positive antiretroviral therapy attendees and human immunodeficiency virus-negative sexually transmitted infection attendees. Indian J Sex Transm Dis AIDS. 2016;37(1):94. [Google Scholar]
Desikan P, Khan Z. Prevalence of hepatitis B and hepatitis C virus co-infection in India: a systematic review and meta-analysis. Indian J Med Microbiol. 2017 Jul-Sep;35(3):332-9. [PubMed] [Google Scholar]
Chakravarty R, Pal A. Insights into human immunodeficiency virus-hepatitis B virus co-infection in India. World J Virol. 2015;4(3):255-64. [Google Scholar]
Darak S, Panditrao M, Parchure R, Kulkarni V, Kulkarni S, Janssen F. Systematic review of public health research on prevention of mother-to-child transmission of HIV in India with focus on provision and utilization of cascade of PMTCT services. BMC Public Health. 2012 May;12:320. [PubMed] [Google Scholar]
National AIDS Control Organization [Internet]. Prevention of parent to child transmission (PPTCT); [cited 2021 Jun 1]. Available from: http://naco.gov.in/prevention-parent-child-transmissionpptct
Hawkes S, Santhya KG. Diverse realities: sexually transmitted infections and HIV in India. Sex Transm Infect. 2002 Apr;78 Suppl 1(Suppl 1):i31-9. [PubMed] [Google Scholar]
World Bank. World Development Report 1993: Investing in Health. New York: Oxford University Press for the World Bank; 19993. [Google Scholar]
Solomon SS, Mehta SH, Srikrishnan AK, Vasudevan CK, Mcfall AM, Balakrishnan P, Anand S, Nandagopal P, Ogburn EL, Laeyendecker O, Lucas GM, Solomon S, Celentano DD. High HIV prevalence and incidence among MSM across 12 cities in India. AIDS. 2015 Mar;29(6):723-31. [PubMed] [Google Scholar]
Copyright (c) 2021 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.